Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (674)	5/15/2005 4:30:02 PM
From: Icebrg	Read Replies (1) of 946

It may raise some eyebrows, yes. But will be enough for approval? I don't think so. 32 patients in the control arm is IMHO not enough. The reason there was a choice and that so few choose the vinorelbine arm was of course that it was known to bring little efficacy. Dr. Corey Langer's presentation of the Stellar 3 results is btw. now available with audio and slides at: asco.org It was a big mistake to include the East Europeans in this trial. They were not sick enough or alternatively Russian doctors are much better than those in the US, Canada and Europe. Considering everything I believe CTIC's chances of bringing home an approval look better now. But it will take time. Maybe the results will be considered to be promising enough to bring in a partner and some much-needed cash. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next